References: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information Parsippany, NJ. Teva Neuroscience, Inc. 2. Frank S, Testa CM, Stamler D, et al; Huntington Study Group ARC-HD Investigators. Long-term efficacy and safety of deutetrabenazine for chorea in Huntington's disease: results from the ARC-HD open-label study. Poster presented at: the 27th Annual Meeting of the Huntington Study Group (HSG); October 29-31, 2020. 3. Burgess JC, Davis B, Fogarty E, et al. Caregiver Guide for Mid to Late Stage Huntington's Disease: For Long-Term Care Facilities and In-Home Care Agencies. Huntington's Disease Society of America; 2014. Accessed January 28, 2022. http://hdsa.org/wp-content/uploads/2015/04/CaregiverGuide_Mid_Late_StageHD.pdf 4. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.
First goal of the study1,2
To measure the effectiveness of AUSTEDO on:
- HD chorea symptoms using the Total Maximal Chorea (TMC) score.
- TMC score progress before, during, and at the end of the 12-week study.
Second goal of the study1,2
To evaluate the effects of AUSTEDO on:
- Overall HD symptoms, as reported by people and their doctors.
- Limitations on people's ability to perform daily activities.
About the study1:
90 people with HD chorea were studied for 12 weeks.
45 people were selected to take AUSTEDO (deutetrabenazine) and 45 people were selected to take placebo (inactive tablets).
Involuntary movements were measured at the beginning and end of the study, with movements also being observed at intervals throughout the 12-week period.
Medications people taking austedo were able to continue throughout the trial:
Understanding the TMC score
The TMC score is used to determine the effectiveness of HD chorea treatment. Seven parts of the body—including the face, mouth, arms, and legs—are scored from 0 to 4, with 0 indicating no chorea. A complete TMC score ranges from 0 to 28. The lower the score, the less chorea, or involuntary movements, exhibited by the person.1,2
More details about the study
23 – 74
Mean CAG Repeat Length2:
TMC Score at the Beginning of the study2:
Switching from tetrabenazine1,2
If your doctor recommends switching to AUSTEDO from tetrabenazine, you can start AUSTEDO the day after you stop tetrabenazine. This means you can continue treating your HD chorea without missing a dose.
In a clinical study, 37 people with HD chorea switched overnight from tetrabenazine to AUSTEDO. People in the study received AUSTEDO at approximately half the dose of tetrabenazine.
Are you a healthcare professional?
The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?
You are about to leave this site
You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.